Treatment for Gram-Negative Bacteremia

Initial Empiric Therapy

For critically ill patients with suspected gram-negative bacteremia, the American College of Physicians recommends initiating immediate dual antibiotic therapy with an anti-pseudomonal beta-lactam plus an aminoglycoside 1, 2
The Infectious Diseases Society of America suggests using meropenem 1-2 grams IV every 8 hours PLUS an aminoglycoside (gentamicin or tobramycin 5-7 mg/kg/day or amikacin 15-20 mg/kg/day) as an empiric regimen 1, 2
The American College of Physicians also recommends cefepime 2 grams IV every 8 hours PLUS an aminoglycoside as an alternative empiric regimen 1, 2
Piperacillin-tazobactam 4.5 grams IV every 6 hours PLUS an aminoglycoside is another recommended empiric regimen 1, 2

The American College of Physicians recommends administering carbapenems as extended infusions (3-hour infusion for meropenem) to optimize pharmacodynamics 2
The Infectious Diseases Society of America suggests using therapeutic drug monitoring for aminoglycosides to optimize efficacy and minimize nephrotoxicity 2

The American College of Physicians states that combination therapy is non-negotiable in high-risk scenarios, including severe sepsis or septic shock 1, 2
The Infectious Diseases Society of America recommends dual therapy for patients with profound neutropenia (<100 cells/μL) with persistent granulocytopenia 3
The American College of Physicians also recommends dual therapy for suspected or confirmed Pseudomonas aeruginosa infection 1, 3
Dual therapy is also recommended for patients with known colonization with multidrug-resistant organisms 1
The Infectious Diseases Society of America suggests dual therapy for patients with hemodynamic instability 4

The American College of Physicians recommends using a carbapenem instead of piperacillin-tazobactam or cephalosporins in settings with high ESBL prevalence (>10-20%) 1
In settings with low ESBL prevalence, piperacillin-tazobactam is an appropriate choice 1
The Infectious Diseases Society of America suggests using polymyxin (colistin) combination therapy or ceftazidime-avibactam for carbapenem-resistant gram-negative bacilli 2

The American College of Physicians recommends de-escalating from combination to single-agent therapy based on susceptibility testing once culture and susceptibility results are available (typically 48-72 hours) 1, 2
The Infectious Diseases Society of America suggests discontinuing the aminoglycoside after 3-5 days once clinical improvement is evident and susceptibility confirms adequate beta-lactam coverage 1
The American College of Physicians recommends continuing the beta-lactam as monotherapy if the organism is susceptible 1, 2

The American College of Physicians recommends treating uncomplicated gram-negative bacteremia for 7 days total 1, 2
The Infectious Diseases Society of America suggests extending therapy to 14 days for complicated infections, including endocarditis 5, suppurative thrombophlebitis 1, metastatic infection (e.g., osteomyelitis, abscess) 4, persistent bacteremia beyond 72 hours despite appropriate therapy 1, and catheter-related bloodstream infection with retained long-term catheter 5

The Infectious Diseases Society of America recommends removing short-term intravascular catheters in all cases of catheter-related gram-negative bacteremia 5, 2
For long-term tunneled catheters or implanted devices, removal is recommended if bacteremia persists beyond 72 hours of appropriate therapy 5, 2

The Infectious Diseases Society of America recommends using broad-spectrum monotherapy with antipseudomonal activity (cefepime, meropenem, or piperacillin-tazobactam) as initial empiric therapy for febrile neutropenia with suspected gram-negative infection 4, 2
The American College of Physicians suggests adding vancomycin or other gram-positive coverage ONLY if there is evidence of catheter-associated infection, skin/soft tissue infection, or hemodynamic instability 4
For patients with severe and persistent granulocytopenia (<100 cells/μL), the Infectious Diseases Society of America recommends maintaining combination therapy with beta-lactam plus aminoglycoside 3, 1

The American College of Physicians warns against using monotherapy in critically ill patients, those with profound neutropenia, or suspected P. aeruginosa infection, as outcomes are significantly worse 3, 1
The Infectious Diseases Society of America advises against continuing combination therapy for the full treatment course once susceptibility confirms single-agent adequacy, as this increases toxicity without benefit 1
The American College of Physicians also warns against delaying antibiotic administration while awaiting culture results, as early appropriate therapy significantly reduces mortality and prevents septic shock 1

Ertapenem may be preferred over meropenem/imipenem for bloodstream infections without septic shock to preserve broader-spectrum carbapenems for more severe infections, according to the Clinical Microbiology and Infection guidelines 6
Carbapenems remain the preferred treatment for serious infections caused by AmpC-producing organisms, as suggested by recent evidence in Clinical Microbiology and Infection 6
Avoid aminoglycosides in combination with other nephrotoxic drugs or in patients with renal dysfunction, as recommended by Clinical Microbiology and Infection 6